Methylfenidaat Hcl Retard Teva

Methylphenidate Hydrochloride, the active ingredient in Methylfenidaat Hcl Retard Teva, is a central nervous system stimulant presented as an extended‑release tablet for oral use. It is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy in children, adolescents, and adults.

GNH USA supplies Methylfenidaat Hcl Retard Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, across the EU and other markets. The company ensures quality compliance with EU pharmacopeial standards.

Methylfenidaat Hcl Retard Teva is used in central nervous system stimulant therapy for neurobehavioral disorders.

- ADHD: improves attention, reduces hyperactivity and impulsivity in children, adolescents, and adults. - Narcolepsy: decreases excessive daytime sleepiness and improves wakefulness. - Adult attention disorders: helps maintain focus during daily activities in adults with ADHD.

Methylfenidaat Hcl Retard Teva may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced hunger leading to weight loss. - Headache: mild to moderate cranial pain. - Stomach pain: abdominal discomfort or cramps. - Nausea: feeling of sickness, sometimes with vomiting. - Irritability: mood changes and increased agitation.

Serious or Rare Side Effects: - Cardiovascular events: tachycardia, hypertension, or arrhythmias. - Psychotic symptoms: hallucinations or delusional thoughts. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Priapism: prolonged painful erection. - Seizures: convulsive episodes in susceptible individuals. - Sudden unexplained death: rare but reported in patients with structural heart disease.

When prescribing Methylfenidaat Hcl Retard Teva, clinicians should observe several safety considerations.

- Cardiovascular assessment: evaluate history of heart disease, hypertension, or arrhythmias before initiating therapy. - Psychiatric monitoring: watch for mood swings, anxiety, or emergence of psychotic symptoms during treatment. - Growth monitoring in children: regularly record height and weight to detect potential growth suppression. - Substance‑use risk: assess for potential misuse or dependence, especially in adolescents. - Drug interaction review: check concomitant medications that may affect methylphenidate levels or cardiovascular status. - Store at ambient temperature: keep below 25 °C in the original container, protected from moisture and light.

Methylfenidaat Hcl Retard Teva can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - MAO inhibitors: concurrent use may cause hypertensive crisis or severe serotonin syndrome. - Other central nervous system stimulants: combined effect can increase cardiovascular strain and risk of agitation. - Certain antidepressants (e.g., tricyclics, SSRIs): may raise methylphenidate plasma concentrations, enhancing side‑effects.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: methylphenidate may reduce their blood‑pressure‑lowering effect. - Antacids or proton‑pump inhibitors: can affect absorption rate of the extended‑release tablet. - Seizure‑threshold lowering drugs: may increase risk of seizures when used together. - Oral contraceptives: possible reduction in contraceptive efficacy. - Alcohol: may exacerbate central nervous system stimulation and cardiovascular effects.